Aptevo Therapeutics Net Income 2014-2022 | APVO

Aptevo Therapeutics net income from 2014 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Aptevo Therapeutics Annual Net Income
(Millions of US $)
2021 $-28
2020 $-18
2019 $-40
2018 $-54
2017 $7
2016 $-112
2015 $-59
2014 $-51
2013 $
Aptevo Therapeutics Quarterly Net Income
(Millions of US $)
2022-09-30 $-8
2022-06-30 $28
2022-03-31 $-8
2021-12-31 $-6
2021-09-30 $-7
2021-06-30 $-8
2021-03-31 $-7
2020-12-31 $-7
2020-09-30 $-7
2020-06-30 $-7
2020-03-31 $3
2019-12-31 $-8
2019-09-30 $-7
2019-06-30 $-13
2019-03-31 $-12
2018-12-31 $-14
2018-09-30 $-13
2018-06-30 $-13
2018-03-31 $-14
2017-12-31 $-10
2017-09-30 $38
2017-06-30 $-11
2017-03-31 $-10
2016-12-31 $-15
2016-09-30 $-72
2016-06-30 $-13
2016-03-31 $-13
2015-12-31
2015-09-30 $-13
2015-06-30 $-18
2014-12-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.011B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00